Evidence map›Paper›PMID 32585853›Full record

ArticleGenes2020

Clinical Relevance of +936 C>T

Sandra Ballester, Begoña Pineda, Patricia Rodrigues, Eduardo Tormo, María José Terol, Pilar Eroles

Open access · goldAbstract read
In one paragraph

Article in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Genes · 2022
    Article
  2. Study of the Association betweenJournal of personalized medicine · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sandra BallesterBiomedical Research Institute INCLIVA, 46010 Valencia, Spain.
Begoña PinedaBiomedical Research Institute INCLIVA, 46010 Valencia, Spain.
Patricia RodriguesBiomedical Research Institute INCLIVA, 46010 Valencia, Spain.
Eduardo TormoBiomedical Research Institute INCLIVA, 46010 Valencia, Spain.ORCID 0000-0002-2255-785X
María José TerolBiomedical Research Institute INCLIVA, 46010 Valencia, Spain.
Pilar ErolesBiomedical Research Institute INCLIVA, 46010 Valencia, Spain.
INCLIVA Health Research Institute · ESHospital Clínico Universitario de Valencia · ESUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiogenesis process contributes to the pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL) being the levels of VEGFA and bFGF higher in patients than in healthy controls. Our aim was to evaluate the implication of angiogenesis factors genetic variants in the predisposition to B-CLL and their association with clinical factors and survival. We performed a population-based case-control study in 224 Spanish B-CLL patients and 476 healthy randomly selected controls to evaluate susceptibility to developing B-CLL. Six polymorphisms were evaluated: rs1109324, rs1547651, rs3025039 (+936 C>T), rs833052 of the

Indexed as

Genetic Predisposition to DiseaseAdultAgedAged, 80 and overFemaleFibroblast Growth FactorsGenetic Association StudiesGenotypeHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPolymorphism, Single NucleotideVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Fibroblast Growth FactorsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1VEGFA protein, humanchronic lymphocytic leukemia riskfibroblast growth factorpolymorphismsvascular endothelial growth factor

Identifiers

PMID32585853
PMCPMC7349122
OpenAlexW3036758993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.